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DDiscussion
Dr Vinod H. Thourani (Atlanta, Ga). My disclosure is that I am
a researcher in the pivotal trial for the Perceval (Sorin Biomedica
Cardio Srl, Saluggia, Italy) system here in the United States.
I thank the Association for the privilege to discuss this
important and timely presentation, and I congratulate you for an
excellent presentation and your multinational study group for their
contribution.
Without rehashing the entire conclusions, the authors report on
94 patients undergoing AVR +CABG and 220 patients undergoing
isolated AVR. On the basis of a euroSCORE II of 9, I would
consider this to be more of a medium-risk population than a
high-risk population. I have 3 questions for you.
You didn’t talk about this much as far as resource use, but the
proposed advantage in some ways to the sutureless valve platform
is decreased aortic crossclamp time, which you have shown, and
this should transpose to some decreased intensive care unit
(ICU) and length of stay. Did you see that in your sutureless valves,
did you see a decreased length of stay, and what was your length of
stay for the ICU and overall length of stay?
Dr Antonino S. Rubino.We believe that reducing crossclamp-
ing and cardiopulmonary bypass time may positively influence the
immediate postoperative outcomes. However, one of the major
limits of our study is that it is multicentric, and we have no
uniform policy in the different centers about when to discharge,
for example, patients from the ICU. So it could be difficult to
generalize on this topic.
Dr Thourani. In your article, you show that the overall length
of stay was 13 days and ICU stay was 3 days. So I think we need to
be cautious when transposing sutureless valve technology to over-
all decreased resource use.
The second question is with your results, and looking
specifically at the AVR + CABG population, especially in those
patients with a euroSCORE greater than 10, have you stopped
using the Perceval valve in those patients in whom you are showing
a relatively higher mortality in all respects?
Dr Rubino. No, we don’t stop performing this procedure. We
all know that the need for associated CABG increases the operative
risk in this cohort of patients, and that the use of a sutureless
prosthesis might improve postoperative outcomes. We have also
shown in this presentation that the use of this prosthesis might
be more beneficial in those patients with a high-risk profile. So
we still keep on performing associated CABG.
Dr Thourani. The last question is more of a philosophical
question. I know that you also do transcatheter aortic valves. After
seeing these data, which patients would receive a stented valve,The Journal of Thoracic and Caa sutureless valve, or a transcatheter valve, because now we have
3 different options for our patients?
Dr Rubino. This allows me to give you a wider opportunity to
answer you. Again, I cannot answer about the policies in the other
centers elsewhere but only about the policy in our center in
Catania. We also do transcatheter valves, and we started with the
transaortic and transapical approach.
We discuss the cases of high-risk patients with our cardiolo-
gists. We do not believe that the cutoff should be pointed out
only by the euroSCORE, because there are some patients referred
to TAVI from local cardiologists who come back to our surgical
cohort, and there are some patients from the surgical cohort who
we send for TAVI. For an indication, we don’t have to rely only
on the age, for example, or the euroSCORE but also on other
severe comorbidities, such as severe neurologic dysfunction,
malignancies, or poor expected life. In these last situations, we
send them to the TAVI cohort.
We are happy to have these sutureless options, because this
allows us to widen the therapeutic options for our population. In
normal-risk patients, a standard conventional procedure should
be the optimal solution. The sutureless valve allows us to increase
the volume of a minimally invasive approach, which is also one of
the most frequent reasons that the cardiologists have when they
propose a TAVI, which is actually minimally invasive, to a patient.
So this prosthesis allows us to improve the minimally invasive
program in the center, and those patients who are at high surgical
risk independently from the mere euroSCORE are sent to TAVI.
Dr Thourani. Congratulations. This is a great article.
Dr Harold L. Lazar (Boston, Mass). I know you don’t have any
controls, but would you estimate how much crossclamp time, based
on your own series of isolated AVRs, you save with this technique?
Dr Rubino. In the standard conventional procedure, it is
40 minutes. If you put in stitches, you will need approximately
35 or 40 minutes of crossclamping. We tried and are implanting
some prostheses with running sutures that also allow us to reduce
the crossclamping time significantly. With this sutureless
prosthesis, our mean crossclamping time is approximately 23
minutes in our center. So there is a significant reduction. But one
of the key messages is that realistically with this prosthesis we
can move toward a minimally invasive approach.
Dr Lazar. Briefly, what technical tricks have you learned as far
as putting these valves in, especially with debriding the annulus?
Dr Rubino. This valve is particularly useful in those cases
when you do not want to manipulate the aorta. We have 2 cases
of almost porcelain aorta. We just dids a transverse aortotomy
approximately 1.5 cm above the sinotubular junction, more or
less at the level of the fat pad. We removed the valve, and we
put the valve in straight without touching the calcium.
To achieve a perfect and complete adhesion of the valve to the
annulus and to the root, apart from the respect of the geometric
relationship I showed before, it is more important to create an
almost perfect circular geometry. In our center we try to decalcify
the annulus almost completely, but what is really important with
this valve is to create a circular geometry. In the past before the
XL was available, we had cases of rescue surgery after TAVI,
and the annulus was large. So we performed a partial
decalcification, but we recreated a circular anatomy and put an L
inside, and the patient went home without any paravalvular leak.rdiovascular Surgery c Volume 148, Number 3 871
